top of page

Biomimetic artificial spider silk 

A hidden gem in the world of advanced materials innovation.

350 000 €

Co-investment

53 Awards

Bla bla bla

95%

Better biological compatibility
kv2.jpg

Welcome to PrintyMed

At PrintyMed, we are revolutionizing the future of medicine and materials through the innovative power of biomimetic spider silk. Founded in 2023 by organic chemistry, business, and medicine experts, we are dedicated to creating cutting-edge solutions that enhance lives and transform industries.

 

We aim to advance healthcare and sustainable innovation with unmatched biocompatibility and precision.

About Us

PrintyMed was born from a shared vision to bridge the gap between groundbreaking science and real-world medical applications. Established in January 2023 by three co-founders with expertise in organic chemistry, business strategy, and medicine, our company stands at the crossroads of innovation and practicality.

241125-1-64.jpg

We collaborate closely with the Latvian Institute of Organic Synthesis, leveraging its state-of-the-art biomimetic spider silk technology to develop solutions that transform patient care and enhance industry standards. Each member of our founding team brings a unique perspective, combining scientific rigor, entrepreneurial insight, and a deep understanding of medical needs to shape the future of biomedicine.

​

​

Our mission is not just about creating materials — it’s about redefining possibilities. Whether it’s replacing invasive procedures with advanced prostheses, accelerating research with organ-on-a-chip membranes, or crafting sustainable beauty products, PrintyMed is driven by the desire to improve lives.
_DSC7149.jpg

Our Technology: Pioneering Innovation

At the heart of PrintyMed is our proprietary biomimetic spider silk technology, developed in collaboration with the Latvian Institute of Organic Synthesis. Engineered to replicate the natural spinning process of spider silk, our technology combines advanced protein engineering and scalable production methods to achieve extraordinary results.

Key Features of Biomimetic Spider Silk Technology

Our technology is patented and was recognized as one of the most significant achievements in Latvian science in 2024.

Unmatched Strength and Flexibility

Ideal for medical applications requiring robust yet adaptable materials.

Customizable

Properties

Silk fibers can be tailored to specific applications, ensuring optimal performance in diverse industries.

Non-animal-based

Our material is produced in bacteria without employing any animal-based material.

Biocompatibility

at its Core

Facilitates cell adhesion, regeneration, and integration into human tissues.

Sustainable and

Eco-Friendly

Our process uses water as the sole solvent, eliminating pollution and reducing environmental impact.

Our Breakthrough Production Process

Protein Design and Synthesis

Dope Formation

Fiber Spinning

Industrial Scalability

Leveraging biomimetic principles, we engineer proteins with optimal structural and functional properties.

Proteins are processed into dope that serve as the foundation for spinning silk fibers.

Our advanced biomimetic spinning method replicates the natural process, producing fibers with unparalleled strength and elasticity.

A scalable manufacturing technology has been developed in

lab-scale bioreactors applicable for industrial applications.

Applications of Biomimetic Spider Silk

Our technology is reshaping industries through applications that include:

1

Regenerative Medicine

Creating artificial organs and scaffolds.

2

Medical Devices

Advanced heart valve prostheses, wound dressing and organ-on-a-chip membranes.

3

Cosmetic Innovation

High-end skincare and haircare formulations.

Through rigorous research and collaboration, PrintyMed continues to push the boundaries of biomimetic technology to deliver transformative solutions.

Our Solutions

1. Organs-on-a-Chip Membranes

Accelerating research and innovation, our membranes are a game-changer for drug screening, disease modeling, and future food testing. Engineered from biomimetic spider silk, they provide unmatched support for cell cultures in microfluidic environments.

2. Cosmetic Ingredients

Our biomimetic spider silk proteins bring regenerative properties to the world of high-end cosmetics. As a sustainable and innovative raw material, it enables groundbreaking formulations for skincare and haircare professionals.

3. Heart Valve Prostheses

We are pioneering durable and biocompatible heart valve prostheses made from biomimetic spider silk. By addressing the limitations of current solutions, our valves promise longer lifespans, reduced clot risks, and fewer invasive surgeries.

4. Advanced Wound Dressings

Leveraging the exceptional properties of biomimetic spider silk, PrintyMed is creating next-generation wound dressings that offer superior healing capabilities. These dressings promote cell regeneration, reduce infection risks, and provide unparalleled comfort and adaptability. Ideal for chronic wounds, burns, and surgical applications, our solutions represent a significant leap forward in wound care technology.

5. Artificial Organs and Scaffolds

Harnessing the potential of biomimetic spider silk, PrintyMed is advancing the development of artificial organs and scaffolds to address the global shortage of transplantable organs. Our silk’s unparalleled cell adhesion and customization capabilities enable the creation of biocompatible, patient-specific solutions. These innovations promise to redefine regenerative medicine and improve the quality of life for millions worldwide.

Why Choose PrintyMed?

1

Our solutions redefine industry standards, offering unrivaled performance and sustainability.

Innovation-Driven
edit--DSC7165.jpg

2

Partnering with innovative companies and research centres in biotech, cosmetics, and medical technology.

Collaborative Approach
1-147.jpg

3

Made from renewable resources. We offer proteins, hydrogel, and fibers for medical and cosmetic industries, ensuring zero waste.

Future-Focused
1732609171001.jpeg

The Founders

Dedication. Expertise. Passion.

jekaterina-romanova.png
Jekaterina Romanova

CEO

10+ years in med-tech start-ups, economist, EU funding expert.

Prof.-Gints.png
Prof. Gints Smits 

CTO

Head of  the Laboratory, Artificial spider silk researcher for 7+ years.

sandra.png
Dr. Sandra Treide 

CMO

Medical expert, 2 successfully commercialized medical technologies.

PhD-Viktors.png
PhD Viktors
Romanuks

COO

Scientist, Artificial spider silk researcher for 5+ years.

Prof.-Kristaps-Jaudzems.png
Prof. Kristaps Jaudzems

CSO

Dean of the University, Artificial spider silk researcher for 10+ years, Author of the technology.

avīze.png
Our Publications

(23.03.2022.) Engineered Spider Silk Proteins for Biomimetic Spinning of Fibers with Toughness Equal to Dragline Silks Tina Arndt, Gabriele Greco, Benjamin Schmuck, Jessica Bunz, Olga Shilkova, Juanita Francis, Nicola M Pugno, Kristaps Jaudzems, Andreas Barth, Jan Johansson, and Anna Rising*  - Advanced Functional Materials; https://doi.org/10.1002/adfm.202200986

 

(07.04.2022.) The dimerization mechanism of the N-terminal domain of spider silk proteins is conserved despite extensive sequence divergence; Médoune Sarr1 , Kristine Kitoka2 , Kellie-Ann Walsh-White1 , Margit Kaldmäe3 , Rimants Metlans2 , Kaspar Tars4 , Alessandro Mantese5 , Dipen Shah5 , Michael Landreh3 , Anna Rising6,7 , Jan Johansson1,7, Kristaps Jaudzems2,*, and Nina Kronqvist1,7,*; Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology,  https://doi.org/10.1016/j.jbc.2022.101913;

 

(14.06.2022.) Solution Structure of Tubuliform Spidroin N-Terminal Domain and Implications for pH Dependent Dimerization; Megija Šede, JÄ“kabs Fridmanis , Martins Otikovs 1 , Jan Johansson , Anna Rising , Nina Kronqvist  and Kristaps Jaudzems*; Frontiers in Molecular Biosciences; https://doi.org/10.3389/fmolb.2022.936887;

 

(15.08.2022.) Spidroin N-terminal domain forms amyloid like fibril based hydrogels and provides a protein immobilization platform; Tina Arndt , Kristaps Jaudzems, Olga Shilkova , Juanita Francis, Mathias Johansson , Peter R. Laity, Cagla Sahin , Urmimala Chatterjee , Nina Kronqvist, Edgar Barajas-Ledesma, Rakesh Kumar , Gefei Chen , Roger Strömberg , Axel Abelein , Maud Langton , Michael Landreh , Andreas Barth, Chris Holland , Jan Johansson1 & Anna Rising ; https://doi.org/10.1038/s41467-022-32093-7

Get in Touch

SIA PrintyMed

Reg. No. 40203456040

  • LinkedIn
Contact Us

Thanks for submitting!

Partners & Investors
Investors6.jpg

© 2024 PrintyMed. All Rights Reserved.

bottom of page